Knights of Columbus Asset Advisors’s Edwards Lifesciences EW Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-9,325	Closed	-$615K	–	397
2024 Q3	$615K	Sell	9,325 -11,955	-56%	-$869K	0.04%	264
2024 Q2	$1.97M	Buy	21,280 +100	+0.5%	+$8.86K	0.13%	217
2024 Q1	$2.02M	Buy	21,180 +10,459	+98%	+$879K	0.15%	198
2023 Q4	$817K	Buy	10,721 +37	+0.3%	+$2.57K	0.05%	262
2023 Q3	$740K	Buy	10,684 +288	+3%	+$23.1K	0.07%	251
2023 Q2	$981K	Hold	10,396	–	–	0.09%	245
2023 Q1	$860K	Buy	+10,396	New	+$817K	0.08%	241

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Knights of Columbus Asset Advisors's EW Position: Q4 2024 in Review

Knights of Columbus Asset Advisors sold out of Edwards Lifesciences (EW) in Q4 2024, closing a stake of 9,325 shares — an estimated $615K sold.

Knights of Columbus Asset Advisors first reported a position in EW in Q1 2023 and held it in 7 quarters. The position peaked at $2.02M in Q1 2024. 1,227 funds tracked by Wall St. Rank hold EW as of Q4 2024.

Knights of Columbus Asset Advisors reported no remaining Edwards Lifesciences position as of Q4 2024 after selling out during the quarter.
Knights of Columbus Asset Advisors sold 9,325 Edwards Lifesciences shares in Q4 2024, an estimated $615K.
Knights of Columbus Asset Advisors first reported a position in Edwards Lifesciences in Q1 2023 and held it in 7 quarters.
Knights of Columbus Asset Advisors's Edwards Lifesciences position peaked at $2.02M in Q1 2024.
1,227 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2024.

Based on Knights of Columbus Asset Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.